- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2013
- Public Summary Document (PSD) November 2013 PBAC Meeting - PDF
Dolutegravir – November 2013
Dolutegravir, tablet, 50 mg, Tivicay®
Last updated
8 November 2023